Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study

FUTURE ONCOLOGYAHEAD OF PRINTCLINICAL TRIAL PROTOCOL

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study

Sanne Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Jos Beijnen, Rene Bernards, Jan Schellens & Sofie Wilgenhof

Published Online:3 Mar 2020https://doi.org/10.2217/fon-2020-0023

View Article

Tools

Share

Abstract

The clinical benefit of treatment with BRAF- and MEK-inhibitors in melanoma is limited due to resistance associated with emerging secondary mutations. Preclinical and clinical studies have shown that short-term treatment with the HDAC inhibitor vorinostat can eliminate cells harboring these secondary mutations causing resistance. This proof of concept study is to determine the efficacy of sequential treatment with vorinostat and BRAFi/MEKi in resistant BRAFV600E mutant melanoma. The primary aim is demonstrating anti-tumor response of progressive lesions according to RECIST 1.1. Secondary end points are to determine that emerging resistant clones with a secondary mutation in the MAPK pathway can be detected in circulating tumor DNA and purged by short-term vorinostat treatment. Exploratory end points include pharmacokinetic, pharmacodynamic and pharmacogenetic analyses (NCT02836548).



Keywords:

BRAF inhibitorBRAFV600E mutationhistone deacetylase inhibitorMEK inhibitormelanomametastaticresistance